The government set up a department called the National Pharmaceutical Pricing Authority (NPPA) to control the prices of medicines in India. This department is tasked with making sure medicine is affordable but also available to everyone. Therefore, NPPA revised the ceiling price of 11 formulations to meet the requirement.
Recently, some companies that make certain medications said they couldn’t make these medications anymore because the prices were too low. To address this issue, the NPPA decided to raise the prices of a small number of essential medicines by 50%.
This decision was made after considering several factors, including how important the medicines are, how long the prices have been controlled, and how much it costs to make the medicines.
List of medicines NPPA revised the ceiling price of 11 formulations
| Sl. No | Name of the Scheduled Formulation | Dosage form & Strength | Unit | Approved revised Ceiling Price (Rs.) | Existing S.O. No. | Date |
| 1. | Benzyl Penicillin | Powder for Injection 10 Lac Units | Each Pack | 14.57 | 1548(E) | 26.03.2024 |
| 2. | Atropine | Injection 0.6mg/ml | 1 ML | 6.86 | 1547(E) Sl. No. 64 | 26.03.2024 |
| 3. | Streptomycin | Powder for Injection 750 mg | 1 Vial | 15.15 | 1547(E) Sl. No. 617 | 26.03.2024 |
| 4. | Streptomycin | Powder for Injection 1000 mg | 1 Vial | 16.29 | 1547(E) Sl. No. 618 | 26.03.2024 |
| 5. | Salbutamol | Tablet 2 mg | 1 Tablet | 0.27 | 1547(E) Sl. No. 596 | 26.03.2024 |
| 6. | Salbutamol | Tablet 2 mg | 1 Tablet | 0.32 | 1547(E) Sl. No. 595 | 26.03.2024 |
| 7. | Salbutamol | Respirator Solution (Solution for Nebulizer 5mg/mL) | 1 ml | 1.02 | 1547(E) Sl. No. 599 | 26.03.2024 |
| 8. | Pilocarpine | Drops 2% | 1 ml | 16.25 | 1547(E) Sl. No. 535 | 26.03.2024 |
| 9. | Cefadroxil | Tablet 500 mg | 1 Tablet | 6.71 | 1547(E) Sl. No. 114 | 26.03.2024 |
| 10. | Desferrioxamine | Powder for injection 500mg | 1 Vial | 282.98 | 1547(E) Sl. No. 705 | 26.03.2024 |
| 11. | Lithium | Tablet 300mg | 1 Tablet | 2.45 | 1547(E) Sl. No. 411 | 26.03.2024 |
Notes:-
(a) All manufacturers of scheduled formulation, selling the branded or generic or both versions of scheduled formulations at a price higher than the ceiling price (plus Goods and Services Tax as applicable) so fixed and notified by the Government, shall revise the prices of all such formulations downward not exceeding the ceiling price specified in column (5) in the above table plus Goods and Services Tax as applicable, if any.
(b) The provisions of para 13(2) of DPCO 2013 would not be applicable to the ceiling price specified in column (5) in respect of the formulations with dosage & strength mentioned in columns (2) and (3) respectively.
(c) The manufacturers may add Goods and Services Tax only if they have paid actually or if it is payable to the Government on the ceiling price mentioned in column (5) of the above-said table.
Also Read: Latest DPCO list 2024 after WPI impact
(d) The ceiling price for a pack of the scheduled formulation shall be arrived at by the concerned manufacturer in accordance with the ceiling price specified in column (5) of the above table as per provisions contained in paragraph 11 of the Drugs (Prices Control) Order, 2013. The manufacturer shall issue a price list in Form–V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to the State Drug Controller and dealers.
(e) As per para 24(4) of DPCO 2013, every retailer and dealer shall display the price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same.
(f) Where an existing manufacturer of scheduled formulation with dosage or strength or both as specified in the above table launches a new drug as per paragraph 2(1) (u) of the DPCO, 2013 such existing manufacturer shall apply for prior price approval of such new drug to the NPPA in Form I as specified under Schedule-II of the DPCO, 2013.
(g) The manufacturers of above said scheduled formulations shall furnish quarterly return to the NPPA, in respect of production / import and sale of scheduled formulations in Form-III of Schedule-II of the DPCO, 2013 through IPDMS. Any manufacturer intending to discontinue production of above said scheduled formulation shall furnish information to the NPPA, in respect of discontinuation of production and / or import of scheduled formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six months prior to the intended date of discontinuation.
(h) The manufacturers not complying with the ceiling price and notes specified hereinabove shall be liable to deposit the overcharged amount along with interest thereon under the provisions of the Drugs (Prices Control) Order, 2013 read with Essential Commodities Act, 1955.
(i) Consequent to the issue of the ceiling price of such formulation as specified in column (2) of the above table in this notification, the price order(s) fixing
References:
- National Pharmaceutical Pricing Authority (NPPA)
- Ministry of Health and Family Welfare-PIB